Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
| Autor: | Koji Iinuma, Shota Fujimoto, Seiichi Kato, Takuya Koie, Hisao Komeda, Mitsuhiro Taniguchi, Masahiro Nakano, Masahiro Uno, Manabu Takai, Takashi Ishida, Yoshito Takahashi, Masayoshi Tamaki |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Technology medicine.medical_specialty Article Subject Science medicine.medical_treatment 030232 urology & nephrology General Biochemistry Genetics and Molecular Biology Group B 03 medical and health sciences Prostate cancer 0302 clinical medicine Internal medicine medicine In patient General Environmental Science Chemotherapy business.industry General Medicine medicine.disease Regimen Docetaxel Cabazitaxel 030220 oncology & carcinogenesis Prednisolone Medicine business medicine.drug |
| Zdroj: | The Scientific World Journal, Vol 2021 (2021) |
| ISSN: | 1537-744X 2356-6140 |
| Popis: | Background. Docetaxel (DOC) was the first regimen that increased the survival and became the standard-of-care in patients with metastatic castration-resistant prostate cancer (mCRPC). However, it is unclear whether switching to second-line chemotherapy or optimal sequencing of cabazitaxel (CBZ) ensures better clinical outcomes. We aimed to evaluate the efficacy of sequential therapy with DOC and CBZ and the effect of the number of prior DOC cycles on oncological outcomes in patients with mCRPC. Methods. We retrospectively included 46 mCRPC patients who received DOC followed by CBZ at quaternary hospitals in Japan between February 2015 and March 2019. Participants received intravenous DOC (40–75 mg/m2) every 3–4 weeks; CBZ (15–25 mg/m2) was administered every 3–4 weeks. Androgen-deprivation therapy and prednisolone 5 mg (twice daily) were administered throughout both regimens. The primary endpoints were overall (OS) and progression-free survival (PFS). The secondary endpoints were the rates of ≥30% and ≥50% reduction in prostate-specific antigen (PSA) levels at chemotherapy initiation. Results. Participants were divided into two groups according to DOC cycles (Groups A and B: ≤6 and ≥7 DOC cycles, respectively). The rates of ≥30% and ≥50% reduction in PSA levels were higher in Group B than in Group A, but there were no significant differences in both groups. Median OS in Groups A and B was 12.7 and 71.0 months, respectively P < 0.001 ; median PFS in Groups A and B was 3 and 12 months, respectively P < 0.001 . Conclusions. Administration of ≥7 cycles of DOC followed by CBZ may improve oncological outcomes in patients with mCRPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text